PanGIA Biotech was featured in GenomeWeb’s 360Dx for its AI-powered approach to non-invasive prostate cancer detection using urine samples.
The article highlights strong early diagnostic performance data, recent validation shared at a leading oncology conference, and PanGIA’s commercialization path across India and the U.S.
Unlike conventional diagnostics that target specific biomarkers, the PanGIA platform analyzes the full range of analytes in a urine sample—capturing proteins, small molecules, salts, and other metabolic by-products—and uses AI to detect patterns associated with cancer.
“The PanGIA Prostate test… represents a very compelling way to meet an unmet need to diagnose prostate cancer early with no social barriers.”
– Caroline Popper, Popper & Co.
The article also explores potential clinical utility, plans for international licensing, and the flexibility of the platform to support detection of additional cancer types.
Note: This article is gated and requires a GenomeWeb subscription to access.
About PanGIA Biotech
PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With a steadfast commitment to research and innovation, PanGIA’s vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit www.PanGIABiotech.com.
Contacts
Joy Capps
Media@PanGIABiotech.com
843-730-3857
References:
¹ Lim FB, et al. “A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes.” The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J